CVS

CVS Health

CVS

Attention (50-day avg)0.01%

Attention rank (50-day avg)#626

Bullish sentiment (50-day avg)96%

Price to earnings ratio23.4

Market capitalization112.4B

Earnings per share3.79

Dividend yield (TTM)3.03%

Revenue (annual)402.1B

Net income (annual)1.7B

Social

What share of all stock conversation is about CVS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0.01% +0.01	0% 0	0.01% -0.02

Sep 27

CVS Health Corporation's stock price is 19.4% below its 52-week high of $110.60, and its FY25 revenue was $402B, 7.8% more than the previous year.
CVS Caremark has reached a settlement with the FTC over an insulin suit, aligning with Express Scripts' earlier deal.
CVS reported Q2 revenue of $106.1B, up 7.3% YoY, and raised its full-year 2026 adjusted EPS guidance to $7.90–$8.10 from $7.30–$7.50.

Generated by AI

Sentiment

Of the messages about CVS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	99.55% +5.53	98.49% +28.14	81.67% +5.88
Bearish	—	0.45% -5.53	1.51% -28.14	18.33% -5.88

Bullish· Sep 25

$CVS is expected to benefit from strong second-quarter 2026 results, with adjusted earnings per share reaching $2.58, up 40% year over year, and revenue topping $106 billion, exceeding analyst consensus by nearly 6%.
A recent expansion of bundled oncology prior authorizations by Aetna, a CVS subsidiary, is expected to drive growth and improve the company's operating performance.
CVS Health Corp. shares are showing signs of a technical rebound, with a 3% increase in afternoon trading, supported by strong underlying financial performance and a raised 2026 adjusted EPS guidance.

Bearish· Jan 28

The proposed 0.09% Medicare Advantage rate increase for 2027 may lead to a decline in CVS Health Corporation's stock, as seen in the recent 14% drop.
The decline in CVS stock is also attributed to UnitedHealth Group's earnings report, which showed a year-over-year revenue decline for the first time since 1995.
The Bank of America price target downgrades for CVS Health Corporation may indicate a value trap, rather than a buying opportunity, as the stock continues to plummet.

Generated by AI

Topics

Of the messages about CVS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Macro	—	0%	15.73%	41.2%
Announcements	—	0%	0.21%	13.71%
Technical Analysis	—	1.16%	6.83%	3.14%
Analysts	—	98.51%	76.92%	26.22%
Earnings	—	0.33%	0.31%	15.21%
Controversies	—	0%	0%	0.53%

Earnings· Aug 5

CVS Health Corporation reported Q2 2026 earnings with revenue of $106.1B, beating estimates by 6.07%, and adjusted EPS of $2.58, beating estimates by 39.14%.
The company raised its full-year 2026 adjusted earnings guidance to $7.90-$8.10 per share, up from the previous range of $7.30 to $7.50, and increased its GAAP diluted EPS and cash flow from operations guidance.
CVS Health's shares fell around 4.1% premarket despite the strong earnings beat, with some analysts citing a muted 2027 outlook and cautious cost warnings as a reason for the decline.

Analysts· Jan 1

CVS Health is among J.P Morgan's top stock picks for 2026, with an overweight rating and a price target of $101.00.
Analysts at J.P Morgan have identified CVS Health as a promising investment opportunity for the upcoming year.
The stock is included in a list of 24 top picks by J.P Morgan, with a specific rating and price target mentioned.

Announcements· Mar 11

CVS Health's Aetna unit settles for $117.7M to resolve False Claims Act allegations related to Medicare Advantage data, potentially leading to volatility in CVS stock.
The settlement addresses alleged inaccurate diagnosis codes submitted by Aetna, a unit of CVS Health, and may impact the PBM industry.
CVS Health is also partnering with Google Cloud on Health100, an AI-powered platform aiming to reimagine healthcare navigation and enhance patient experience.

Controversies· Sep 20

The FTC has sued CVS Health's Caremark, along with two other pharmacy benefit managers, for allegedly inflating insulin prices and boosting profits.
The lawsuit claims that these middlemen artificially inflate costs for patients, although one commenter notes that CVS used to offer a $25 emergency insulin supply without insurance, which they claim is not price gouging.
The FTC may also recommend suing insulin manufacturers in the future, including Eli Lilly, Sanofi, and Novo Nordisk, as part of their investigation into the insulin pricing controversy.

Macro· Feb 25

The post compares CVS to UNH, mentioning UNH's stock price and earnings report, but does not provide any specific information about CVS.
There is no information in the post about CVS's stock price, forecast, or dividend schedule.
The post does not mention any macroeconomic factors that could impact CVS or the healthcare industry.

Technical Analysis· Nov 1

$CVS has broken below $56.20, potentially leading to a drop to $55 or lower.
A bear flag has been confirmed on $CVS, indicating a possible continuation of the downward trend.
The stock's price action is approaching its May 2024 low, which could be a key level for determining the next direction of the trend.

Generated by AI

Community

Of the messages about CVS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	6.29%	16.77%	41.72%
Newcomers	100%	93.71%	83.23%	58.28%

Regulars· Sep 25

The stock price of CVS Health rose by 3% in afternoon trading, staging a technical rebound after eight consecutive sessions of declines.
CVS's strong second-quarter 2026 results, released in August, exceeded analyst consensus, with adjusted earnings per share reaching $2.58, up 40% year over year, and revenue topping $106 billion.
CVS's management raised its 2026 adjusted EPS guidance to $7.90-$8.10, an increase of $0.60 from its previous outlook, and lifted its operating cash-flow forecast to at least $11.5 billion.

Newcomers· Aug 5

CVS Health's stock price dropped around 6% after a strong Q2 earnings report and raised guidance, leaving some investors concerned about the reason behind the decline.
Some investors are focused on the potential loss of CareMark customers next year, which they believe might be the explanation for the drop in stock price.
New investors are excited about the potential for CVS Health's stock to bounce back, with some already buying in on the dip and setting limit orders to take advantage of the situation.

Generated by AI

WHIPPANY, N.J., September 29, 2026--Bayer today announced the launch of MiraSOFT, a new stool softener option from the makers of MiraLAX® with the active ingredient docusate sodium designed to help gently soften hard, dry stools and support more comfortable, easier bowel movements. * MiraSOFT is now available at over 7,000 CVS Pharmacy locations and at cvs.com.

22h agoYahoo Finance

CVS Health (CVS) Falls More Steeply Than Broader Market: What Investors Need to Know

The latest trading day saw CVS Health (CVS) settling at $87.85, representing a -1.44% change from its previous close.

1d agoYahoo Finance

CVS Health Corp. stock underperforms Monday when compared to competitors

1d agoMarketWatch

CVS Health (CVS) Reclaims Its 200 Day EMA, Is The Stock Still A Bargain?

Why CVS Health Stock Is Back On Traders’ Screens CVS Health (CVS) has jumped back into focus after a 4.8% move on September 25 pushed the share price to $89.13 and back above its 200 day EMA. That single session pulled the stock higher even as the broader daily trend still points lower. This has given short term traders fresh technical signals, while longer term investors are assessing whether this latest bounce changes the story. Set against that sudden spike, CVS Health has had a mixed run,...

3d agoYahoo Finance

CVS Group PLC (CVSGF) (FY 2026) Earnings Call Highlights: Revenue Climbs 5. ...

CVS Group PLC (CVSGF) posted solid full-year revenue and EBITDA growth, expanded in Australia, and signaled confidence in returning to its 4%--8% like-for-like range despite softer consumer footfall.

3d agoYahoo Finance

CVS Health Stock Still Looks Good Even If Health Cost Woes Materialize (NYSE:CVS)

4d agoSeeking Alpha

Also Discussed

Investors talking about CVS also mention

#	Name	Attention
1	WBA - Walgreens Boots Alliance, Inc.	——
2	The Cigna GroupCI	0%0
3	OSH - Oak Street Health, Inc.	——
4	Humana Inc.HUM	0%+0
5	Elevance Health, Inc.ELV	0%new
6	UnitedHealth Group IncorporatedUNH	0%-0.02
7	RAD - Rite Aid Corporation	——
8	The Hershey Company Common StockHSY	0%0
9	McKesson CorporationMCK	0%0
10	Altria Group, Inc.MO	0.06%+0.06

CVS Health Corporation

Healthcare
Healthcare Plans

CVS Health Corporation is a diversified healthcare company that provides health solutions across insurance, pharmacy, and care delivery. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments, serving individuals, employers, and other healthcare customers. Its businesses include health insurance products, pharmacy benefit management, retail prescription dispensing, and a broad range of health services delivered in clinics, virtually, and in the home. CVS Health also offers wellness products, vaccination services, and related pharmacy support through its nationwide network. Based in Woonsocket, Rhode Island, CVS Health plays a significant role in connecting insurance, pharmacy access, and care delivery within the U.S. healthcare system.

Website

Location

One CVS Drive

Woonsocket, RI, 02895

United States

Social

What share of all stock conversation is about CVS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0.01% +0.01	0% 0	0.01% -0.02

Sep 27

CVS Health Corporation's stock price is 19.4% below its 52-week high of $110.60, and its FY25 revenue was $402B, 7.8% more than the previous year.
CVS Caremark has reached a settlement with the FTC over an insulin suit, aligning with Express Scripts' earlier deal.
CVS reported Q2 revenue of $106.1B, up 7.3% YoY, and raised its full-year 2026 adjusted EPS guidance to $7.90–$8.10 from $7.30–$7.50.

Generated by AI

Sentiment

Of the messages about CVS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	99.55% +5.53	98.49% +28.14	81.67% +5.88
Bearish	—	0.45% -5.53	1.51% -28.14	18.33% -5.88

Bullish· Sep 25

$CVS is expected to benefit from strong second-quarter 2026 results, with adjusted earnings per share reaching $2.58, up 40% year over year, and revenue topping $106 billion, exceeding analyst consensus by nearly 6%.
A recent expansion of bundled oncology prior authorizations by Aetna, a CVS subsidiary, is expected to drive growth and improve the company's operating performance.
CVS Health Corp. shares are showing signs of a technical rebound, with a 3% increase in afternoon trading, supported by strong underlying financial performance and a raised 2026 adjusted EPS guidance.

Bearish· Jan 28

The proposed 0.09% Medicare Advantage rate increase for 2027 may lead to a decline in CVS Health Corporation's stock, as seen in the recent 14% drop.
The decline in CVS stock is also attributed to UnitedHealth Group's earnings report, which showed a year-over-year revenue decline for the first time since 1995.
The Bank of America price target downgrades for CVS Health Corporation may indicate a value trap, rather than a buying opportunity, as the stock continues to plummet.

Generated by AI

Topics

Of the messages about CVS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Macro	—	0%	15.73%	41.2%
Announcements	—	0%	0.21%	13.71%
Technical Analysis	—	1.16%	6.83%	3.14%
Analysts	—	98.51%	76.92%	26.22%
Earnings	—	0.33%	0.31%	15.21%
Controversies	—	0%	0%	0.53%

Earnings· Aug 5

CVS Health Corporation reported Q2 2026 earnings with revenue of $106.1B, beating estimates by 6.07%, and adjusted EPS of $2.58, beating estimates by 39.14%.
The company raised its full-year 2026 adjusted earnings guidance to $7.90-$8.10 per share, up from the previous range of $7.30 to $7.50, and increased its GAAP diluted EPS and cash flow from operations guidance.
CVS Health's shares fell around 4.1% premarket despite the strong earnings beat, with some analysts citing a muted 2027 outlook and cautious cost warnings as a reason for the decline.

Analysts· Jan 1

CVS Health is among J.P Morgan's top stock picks for 2026, with an overweight rating and a price target of $101.00.
Analysts at J.P Morgan have identified CVS Health as a promising investment opportunity for the upcoming year.
The stock is included in a list of 24 top picks by J.P Morgan, with a specific rating and price target mentioned.

Announcements· Mar 11

CVS Health's Aetna unit settles for $117.7M to resolve False Claims Act allegations related to Medicare Advantage data, potentially leading to volatility in CVS stock.
The settlement addresses alleged inaccurate diagnosis codes submitted by Aetna, a unit of CVS Health, and may impact the PBM industry.
CVS Health is also partnering with Google Cloud on Health100, an AI-powered platform aiming to reimagine healthcare navigation and enhance patient experience.

Controversies· Sep 20

The FTC has sued CVS Health's Caremark, along with two other pharmacy benefit managers, for allegedly inflating insulin prices and boosting profits.
The lawsuit claims that these middlemen artificially inflate costs for patients, although one commenter notes that CVS used to offer a $25 emergency insulin supply without insurance, which they claim is not price gouging.
The FTC may also recommend suing insulin manufacturers in the future, including Eli Lilly, Sanofi, and Novo Nordisk, as part of their investigation into the insulin pricing controversy.

Macro· Feb 25

The post compares CVS to UNH, mentioning UNH's stock price and earnings report, but does not provide any specific information about CVS.
There is no information in the post about CVS's stock price, forecast, or dividend schedule.
The post does not mention any macroeconomic factors that could impact CVS or the healthcare industry.

Technical Analysis· Nov 1

$CVS has broken below $56.20, potentially leading to a drop to $55 or lower.
A bear flag has been confirmed on $CVS, indicating a possible continuation of the downward trend.
The stock's price action is approaching its May 2024 low, which could be a key level for determining the next direction of the trend.

Generated by AI

Community

Of the messages about CVS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	6.29%	16.77%	41.72%
Newcomers	100%	93.71%	83.23%	58.28%

Regulars· Sep 25

The stock price of CVS Health rose by 3% in afternoon trading, staging a technical rebound after eight consecutive sessions of declines.
CVS's strong second-quarter 2026 results, released in August, exceeded analyst consensus, with adjusted earnings per share reaching $2.58, up 40% year over year, and revenue topping $106 billion.
CVS's management raised its 2026 adjusted EPS guidance to $7.90-$8.10, an increase of $0.60 from its previous outlook, and lifted its operating cash-flow forecast to at least $11.5 billion.

Newcomers· Aug 5

CVS Health's stock price dropped around 6% after a strong Q2 earnings report and raised guidance, leaving some investors concerned about the reason behind the decline.
Some investors are focused on the potential loss of CareMark customers next year, which they believe might be the explanation for the drop in stock price.
New investors are excited about the potential for CVS Health's stock to bounce back, with some already buying in on the dip and setting limit orders to take advantage of the situation.

Generated by AI

CVS Health

Social

Sep 27

Bullish· Sep 25

Bearish· Jan 28

Earnings· Aug 5

Analysts· Jan 1

Announcements· Mar 11

Controversies· Sep 20

Macro· Feb 25

Technical Analysis· Nov 1

Regulars· Sep 25

Newcomers· Aug 5

MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option

CVS Health (CVS) Falls More Steeply Than Broader Market: What Investors Need to Know

CVS Health Corp. stock underperforms Monday when compared to competitors

CVS Health (CVS) Reclaims Its 200 Day EMA, Is The Stock Still A Bargain?

CVS Group PLC (CVSGF) (FY 2026) Earnings Call Highlights: Revenue Climbs 5. ...

CVS Health Stock Still Looks Good Even If Health Cost Woes Materialize (NYSE:CVS)

Also Discussed

CVS Health Corporation

Company Information

Location

MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option

CVS Health (CVS) Falls More Steeply Than Broader Market: What Investors Need to Know

CVS Health Corp. stock underperforms Monday when compared to competitors

CVS Health (CVS) Reclaims Its 200 Day EMA, Is The Stock Still A Bargain?

CVS Group PLC (CVSGF) (FY 2026) Earnings Call Highlights: Revenue Climbs 5. ...

CVS Health Stock Still Looks Good Even If Health Cost Woes Materialize (NYSE:CVS)

Also Discussed

Social

Sep 27

Bullish· Sep 25

Bearish· Jan 28

Earnings· Aug 5

Analysts· Jan 1

Announcements· Mar 11

Controversies· Sep 20

Macro· Feb 25

Technical Analysis· Nov 1

Regulars· Sep 25

Newcomers· Aug 5